A novel high-pressure precipitation tandem homogenization technology for drug nanocrystals production - A case study with ursodeoxycholic acid

Pharmaceutical Development and Technology

Volumn 19, Issue 6, 2014, Pages 662-670

  Li, Yu ^a   Wang, Yong ^a   Yue, Peng Fei ^a   Hu, Peng Yi ^a   Wu, Zhen Feng ^a   Yang, Ming ^a   Yuan, Hai Long ^b  

^a JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b BEIJING 302 HOSPITAL   (China)

Author keywords

High pressure precipitation tandem homogenization technology; Nanocrystals; Nanosuspension; Ursodeoxycholic acid

Indexed keywords

HYDROXYPROPYLMETHYLCELLULOSE; METHYLCELLULOSE; NANOCRYSTAL; POLOXAMER; URSODEOXYCHOLIC ACID;

ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DISSOLUTION; DRUG BIOAVAILABILITY; FREEZE DRYING; HIGH PRESSURE PRECIPITATION TANDEM HOMOGENIZATION TECHNOLOGY; HYDROPHOBICITY; NANOTECHNOLOGY; PARTICLE SIZE; POWDER X RAY DIFFRACTION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SCANNING ELECTRON MICROSCOPY; SUSPENSION; THERMAL ANALYSIS; X RAY DIFFRACTION;

CHEMICAL PRECIPITATION; FREEZE DRYING; NANOPARTICLES; PARTICLE SIZE; POWDERS; PRESSURE; SOLUBILITY; SUSPENSIONS; TECHNOLOGY, PHARMACEUTICAL; URSODEOXYCHOLIC ACID;

EID: 84898046970     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2013.819015     Document Type: Article

References (22)

1. Khan AI, Lei L, Norquist AJ, O'Hare D. Intercalation and controlled release of pharmaceutically active compounds from a layered double hydroxide. Chem Commun 2001;22:2342-2343.
2. Porter CJH, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev 2008;60:673-691.
3. Remenar JF, Morissette SL, Peterson ML, et al. Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. J Am Chem Soc 2003;125:8456-8457.
4. Hu J, Johnston KP, Williams RO. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev Ind Pharm 2004;30:233-245.
5. Shakeel F, Faisal MS. Nanoemulsion: a promising tool for solubility and dissolution enhancement of celecoxib. Pharm Dev Technol 2010;15:53-56.
6. Denga Z, Xu S, Li S. Understanding a relaxation behavior in a nanoparticle suspension for drug delivery applications. Int J Pharm 2008;351:236-243.
7. Choi G, Lee JH, Oh YJ, et al. Inorganic-polymer nanohybrid carrier for delivery of a poorly-soluble drug, ursodeoxycholic acid. Int J Pharm 2010;402:117-122.
8. Möschwitzer J, Müller RH. New method for the effective production of ultrafine drug nanocrystals. J Nanosci Nanotechnol 2006;6: 3145-3153.
9. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliver Rev 2001;47:3-19.
10. Van Eerdenbrugh B, Van den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm 2008;364:64-75.
11. Müller RH, Becker R, Kruss B, Peters K. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution, US Patent 5858410, 1999.
12. Liversidge GG, Cundy KC, Bishop JF, Czekai DA. Surface modified drug nanoparticles, US Patent 5145684, 1992.
13. Müller RH, Gohla S, Keck CM. State of the art of nanocrystals - special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm 2011;78:1-9.
14. Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 2006;62:3-16.
15. Salazar J, Ghanem A, Müller RH, Möschwitzer JP. Nanocrystals: comparison of the size reduction effectiveness of a novel combinative method with conventional top-down approaches. Eur J Pharm Biopharm 2012;81:82-90.
16. Ventura CA, Tirendi S, Puglisi G, et al. Improvement of water solubility and dissolution rate of ursodeoxycholic acid and chenodeoxycholic acid by complexation with natural and modified b-cyclodextrins. Int J Pharm 1997;149:1-13.
17. Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm 2006;312:179-186.
18. Mauludin R, Muller RH, Keck CM. Kinetic solubility and dissolution velocity of rutin nanocrystals. Eur J Pharm Sci 2009;36: 502-510.
19. Xia DN, Cui FD, Piao HZ, et al. Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats. Pharm Res 2010;27:1965-1976.
20. Junghanns JUAH, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed 2008;3:295-309.
21. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001;47:3-19.
22. Pu X, Sun J, Wang Y, et al. Development of a chemically stable 10- hydroxycamptothecin nanosuspensions. Int J Pharm 2009;379: 167-173.